Cargando…

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience

Detalles Bibliográficos
Autores principales:	Weinbergerová, Barbora, Čerňan, Martin, Kabut, Tomáš, Semerád, Lukáš, Podstavková, Natália, Szotkowski, Tomáš, Ježíšková, Ivana, Mayer, Jirí
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542832/ https://www.ncbi.nlm.nih.gov/pubmed/36815379 http://dx.doi.org/10.3324/haematol.2022.282263

Ejemplares similares

Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019)

Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
por: Kabut, Tomáš, et al.
Publicado: (2023)

Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic
por: Čerňan, Martin, et al.
Publicado: (2022)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
por: Zaytsev, Daniil, et al.
Publicado: (2020)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Bronchoalveolar lavage fluid and serum 1,3-β-d-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance
por: Weinbergerova, Barbora, et al.
Publicado: (2020)

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
por: Kurimoto, M, et al.
Publicado: (2013)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
por: Russell-Smith, T. Alexander, et al.
Publicado: (2021)

Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use
por: Kovacsova, Flora, et al.
Publicado: (2023)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020)

Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
por: Hååg, Petra, et al.
Publicado: (2022)

COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic
por: Čerňan, Martin, et al.
Publicado: (2021)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia
por: AZUMA, YOSHIKO, et al.
Publicado: (2016)

Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol
por: Muhamad, Nor A, et al.
Publicado: (2020)

Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)
por: Vegunta, Rathnamitreyee, et al.
Publicado: (2022)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
por: Jager, Eva, et al.
Publicado: (2011)

Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a ‘Real-Life’ Study
por: Laurino, Marica, et al.
Publicado: (2020)

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience
por: Açar, İbrahim Halil, et al.
Publicado: (2023)

PB1853: OUTCOMES REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY MANIFESTATIONS AFTER GEMTUZUMAB OZOGAMICIN THERAPY
por: Ayubova, Bella, et al.
Publicado: (2023)

PB1883: IMPLANTATION AND LONG-TERM USE OF PERIPHERALLY-INSERTED CENTRAL CATHETER ARE SAFE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKAEMIA
por: Szotkowski, Tomáš, et al.
Publicado: (2023)

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
por: Niktoreh, Naghmeh, et al.
Publicado: (2019)

Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia
por: Khan, Naeem, et al.
Publicado: (2016)

Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
por: Zhang, Nan, et al.
Publicado: (2020)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
por: Küçükdiler, Ayşe Hilal Eroğlu, et al.
Publicado: (2021)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u8sfcfqi9679kh624fu83e9fit